Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.

The presence of a pathogenic somatic myeloid mutation was not a risk factor for a CVE for patients receiving imatinib at the time of the CVE (OR 1.9, p = 0.409) but was of borderline significance for patients receiving a 2G-TKI at the time of the CVE (OR 3.11, p = 0.072; Supplementary Table S3 ).

also in 446 other papers

Considering the CV event-free survival rate according to the TKI received at the time of the event, the presence of a somatic pathogenic myeloid mutation was of borderline significance for patients who received imatinib at the time of the event ( p = 0.092) but did not reach statistical significance for patients receiving a 2G-TKI at the time of the event (results not shown). 4.

also in 50,127 other papers

The detection of a pathogenic somatic myeloid mutation at diagnosis was a significant CVE risk factor for patients receiving first-line imatinib and first-line 2G-TKI but failed to reach significance for patients receiving imatinib or 2G-TKI at the time of the CVE, perhaps due to a multiple TKI line confounding effect of CVE risks.

also in 976 other papers